NCT05405166
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM treatment 3 active_not_recruiting NCT04640779
Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma treatment 1 recruiting NCT04756401
Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma treatment 2 active_not_recruiting NCT04892264
Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma treatment 1 / 2 completed NCT04956302
Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma treatment 1 terminated NCT01689987
Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma treatment 1 completed NCT02765854
Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement treatment 2 active_not_recruiting NCT03502577
BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma treatment 1 terminated NCT03256045
Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma treatment 2 terminated NCT02948283
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia treatment 1 completed NCT01711528
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma treatment 1 completed NCT03311828
Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma diagnostic 1 completed NCT03202628
Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma treatment 2 completed NCT00966693
Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma treatment 1 / 2 completed NCT04205409
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies treatment 2 active_not_recruiting NCT02633059
Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma treatment 1 / 2 active_not_recruiting NCT02504359
Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma treatment 1 completed NCT03457142
Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy treatment 2 active_not_recruiting NCT04407442
Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab treatment 2 terminated NCT00723099
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer treatment 2 completed NCT04850599
Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma treatment 2 active_not_recruiting NCT03246906
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation treatment 2 active_not_recruiting NCT03605719
Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma treatment 1 completed NCT02861417
Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant treatment 2 active_not_recruiting NCT02095834
Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma treatment 1 completed NCT03399539
Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma treatment 1 completed NCT01794039
Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide treatment 2 completed NCT00789776
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer treatment 1 / 2 completed NCT03763162
Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma treatment 2 active_not_recruiting NCT04205240
Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma treatment 2 terminated NCT02119468
Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma treatment 1 / 2 completed NCT03333746
Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma treatment 2 terminated NCT01231412
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant treatment 3 completed NCT01085214
AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma treatment 2 completed NCT03303950
Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis treatment 2 terminated NCT04579523
²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma treatment 1 not_yet_recruiting NCT05514990
Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial treatment 1 / 2 recruiting NCT04508790
Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma treatment 2 recruiting NCT03701321
Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma treatment 1 / 2 withdrawn NCT03710421
CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma treatment 1 recruiting NCT03506802
TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma treatment 1 withdrawn NCT01527045
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies prevention 2 completed NCT01989598
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma treatment 2 completed NCT05411497
Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma treatment 1 recruiting NCT05363111
Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma treatment 1 recruiting NCT01903811
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma treatment 2 completed NCT03267888
Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma treatment 1 / 2 completed NCT01301807
Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma treatment 1 completed NCT01822509
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant treatment 1 completed NCT01946152
Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma treatment 1 / 2 terminated NCT02086552
Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma treatment 2 completed NCT02509052
Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma treatment 1 / 2 completed NCT02506959
Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma treatment 2 completed NCT03128359
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant supportive_care 2 completed NCT03622775
Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant treatment 2 active_not_recruiting NCT03328936
Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant treatment 2 withdrawn NCT00068718
Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant treatment 1 / 2 completed NCT04090619
Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Caregivers No drug interventions Not Available Not Available active_not_recruiting NCT01955434
SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma treatment 2 completed NCT03878524
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial treatment 1 terminated NCT01028716
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies treatment 2 terminated NCT01163357
Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma treatment 1 active_not_recruiting NCT03841565
Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma treatment 2 withdrawn NCT03017820
VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma treatment 1 recruiting NCT02569320
HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma treatment 1 completed NCT03829020
Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma treatment 1 completed NCT01415882
Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib treatment 2 active_not_recruiting NCT02514382
Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma treatment 1 completed NCT03506360
Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma treatment 2 completed NCT01008462
Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia treatment 2 completed NCT05288062
Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma treatment 2 active_not_recruiting NCT03015792
Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant treatment 1 / 2 terminated NCT02697344
Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma treatment 1 completed NCT01372540
Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia treatment 1 completed NCT03338972
Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma treatment 1 completed NCT05191472
Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies treatment 2 terminated NCT02353572
Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma treatment 1 / 2 terminated NCT02960646
Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies treatment 1 completed NCT03856112
Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma treatment 1 / 2 withdrawn NCT02971410
Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory Multiple Myeloma treatment 0 withdrawn NCT00450814
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma treatment 1 / 2 completed NCT04409314
Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy Not Available Not Available completed NCT05312255
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma treatment Not Available recruiting NCT05391750
Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma treatment 1 recruiting NCT02593123
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis treatment 2 completed